Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25693853 | 0.85 | PTPN11 (0.67) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL13290619 | 0.85 | PTPN11 (0.67) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL29691832 | 0.85 | PTPN11 (0.67) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL21881992 | 0.85 | PTPN11 (0.71) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL24669699 | 0.84 | PTPN11 (0.74) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL7231271 | 0.84 | PTPN11 (0.70) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL31747254 | 0.83 | PTPN11 (0.64) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL26131987 | 0.83 | PTPN11 (0.64) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL4816347 | 0.83 | PTPN11 (0.64) | PTPN11DDB1CRBNADRA2ADRD5 | |
| SCHEMBL7041264 | 0.83 | PTPN11 (0.68) | PTPN11DDB1CRBNADRA2ADRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-8765746-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765746-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PTPN11 4602/4885GAA 323/4885DDB1 333/4885 |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | PTPN11 2214/4885GAA 2881/4885DDB1 1202/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PTPN11 4602/4885GAA 323/4885DDB1 333/4885 |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | PTPN11 2214/4885GAA 2881/4885DDB1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.